Phase I/II Trial of Temsirolimus and Sorafenib in Treatment of Patients with Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

BACKGROUND: MAPK activation and mTOR-dependent signaling are hallmarks of glioblastoma. We conducted a phase I-II study of sorafenib (an inhibitor of Raf-kinase and VEGFR-2) and the mTOR inhibitor temsirolimus in recurrent glioblastoma. METHODS: Patients with recurrent glioblastoma progressing follo...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer
Main Authors: Schiff, David, Jaeckle, Kurt A, Anderson, S. Keith, Galanis, Evanthia, Giannini, Caterina, Buckner, Jan C., Stella, Phillip, Flynn, Patrick J, Erickson, Bradley J, Schwerkoske, John F, Kaluza, Vesna, Twohy, Erin, Dancey, Janet, Wright, John, Sarkaria, Jann N.
格式: Artigo
語言:Inglês
出版: 2018
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5867230/
https://ncbi.nlm.nih.gov/pubmed/29313954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31219
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍